Investors can’t seem to look past yet another cut to
Eli Lilly
full-year guidance, even after the company eked out an earnings and revenue beat and detailed strong sales of a drug many analysts view as key to the future of the pharmaceutical group.
Shares in
Eli Lilly
(ticker: LLY) slipped 0.7% in U.S. premarket trading. The stock had gained 33% this year as of Monday’s close.
